Background: Diffusion-weighted imaging (DWI) has become increasingly valuable in lymph node imaging, yet the clinical utility of this technique in the staging of lymphoma has not been established.
Purpose: To compare whole-body DWI with FDG-PET/CT in the staging of lymphoma patients.
Material And Methods: Thirty-one patients, eight with Hodgkin lymphoma (HL) and 23 with non-Hodgkin's lymphoma (18 aggressive and five indolent) underwent both whole-body DWI, whole-body MRI (T1W and T2W-STIR) and FDG-PET/CT. Lesions on whole-body DWI were only considered positive if they correlated with lesions on T1W and T2W-STIR images. The staging given by each technique was compared, according to the Ann Arbor staging system. Differences in staging were solved using biopsy results, and clinical and CT follow-ups as standard of reference.
Results: The staging was the same for DWI and FDG-PET/CT in 28 (90.3%) patients and different in three (9.7%). Of the 28 patients with the same staging, 11 had stage IV in both techniques and 17 had stages 0-III. No HL or aggressive non-Hodgkin's lymphoma patients had different staging. Three indolent small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) lymphoma had higher staging with DWI when compared with FDG-PET/CT. One small subcutaneous breast lymphoma was not seen but all other extranodal sites were detected by both techniques.
Conclusion: Whole-body DWI is a promising technique for staging of both (aggressive and indolent) non-Hodgkin's lymphoma and HL.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1258/ar.2010.100246 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Introduction Tumor staging is essential for determining treatment strategies and predicting prognosis in cancer patients. Accurate imaging techniques are critical for staging, metastasis screening, treatment response assessment, and recurrence detection. Objective In this prospective study, we aimed to compare the sensitivity of whole-body diffusion-weighted imaging (WB-DWI) with positron emission tomography/computed tomography (PET/CT) in detecting metastases.
View Article and Find Full Text PDFSplenic T2 signal intensity loss on MRI is associated with disease burden in multiple myeloma.
Eur Radiol
November 2024
Department of Medicine V, Multiple Myeloma Section, University Hospital Heidelberg, Heidelberg, Germany.
Article Synopsis
- - The study investigates how changes in spleen signal on various MRI sequences relate to the amount of plasma cell infiltration in the bone marrow of multiple myeloma patients, aiming to find a possible indicator for disease severity.
- - Researchers analyzed 45 newly diagnosed MM patients using whole-body MRI and found that spleen signal intensity negatively correlated with bone marrow plasma cell infiltration, meaning higher infiltration resulted in lower spleen signal.
- - Results suggest a significant association between spleen signal intensity, particularly on T2-weighted images, and tumor burden, providing potential insights for assessing disease in multiple myeloma patients.
Quantification of breast biopsy clip marker artifact on routine breast MRI sequences: a phantom study.
Eur Radiol Exp
November 2024
Department of Radiology, Medical University Innsbruck, Innsbruck, Austria.
Background: To investigate the artifact sizes of four common breast clip-markers on a standard breast magnetic resonance imaging (MRI) protocol in an in vitro phantom model.
Methods: Using 1.5-T and 3-T whole-body scanners with an 18-channel breast coil, artifact dimensions of four breast biopsy markers in an agarose-gel phantom were measured by two readers on images obtained with the following sequences: T2-weighted fast spin-echo short inversion time fat-suppressed inversion-recovery with magnitude reconstruction (T2-TIRM); T1-weighted spoiled gradient-echo with fat suppression (T1_FL3D), routinely used for dynamic contrast-enhanced imaging; diffusion-weighted imaging (DWI), including a readout segmented echo-planar imaging (RESOLVE-DWI) and echo-planar imaging sequence (EPI-DWI).
Enhancing the diagnostic capacity of [F]PSMA-1007 PET/MRI in primary prostate cancer staging with artificial intelligence and semi-quantitative DCE: an exploratory study.
EJNMMI Rep
November 2024
Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, D-69210, Heidelberg, Germany.
Background: To investigate the ability of artificial intelligence (AI)-based and semi-quantitative dynamic contrast enhanced (DCE) multiparametric MRI (mpMRI), performed within [F]-PSMA-1007 PET/MRI, in differentiating benign from malignant prostate tissues in patients with primary prostate cancer (PC).
Results: A total of seven patients underwent whole-body [F]-PSMA-1007 PET/MRI examinations including a pelvic mpMRI protocol with T2w, diffusion weighted imaging (DWI) and DCE image series. Conventional analysis included visual reading of PET/MRI images and Prostate Imaging Reporting & Data System (PI-RADS) scoring of the prostate.
Prediction of non-resectability in tubo-ovarian cancer patients using Peritoneal Cancer Index - A prospective multicentric study using imaging (ISAAC study).
Gynecol Oncol
December 2024
Gynecologic Oncology Centre, Department of Gynecology, Obstetrics and Neonatology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. Electronic address:
Background: The aim was to evaluate the performance of the Peritoneal Cancer Index (PCI) using imaging (ultrasound, contrast-enhanced computed tomography (CT), and whole-body diffusion-weighted magnetic resonance imaging (WB-DWI/MRI) in assessing peritoneal carcinomatosis and predicting non-resectability in tubo-ovarian carcinoma patients.
Methods: This was a prospective multicenter observational study. We considered all patients with suspected primary ovarian/tubal/peritoneal cancer who underwent preoperative ultrasound, CT, and WB-DWI/MRI (if available).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!